suma/抗癌药

BACKGROUND OF THE INVENTION The invention relates to addition products between .alpha.-keto-aldehydes and secondary amines .alpha.-KETO-ALDEHYDES ARE WELL KNOWN AND USUALLY ARE PREPARED THROUGH OXIDATION (Riley, H. L., Morley, J. F., and Friend, N.A.C.: J.Chem.Soc. 1932.1875; Rabjohn, N.: in Organic

FIELD OF THE INVENTION The present invention relates to acid addition salts of the pharmaceutically active compound (3,5-Bistrifluoromethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamin- o)-phenyl]-benzamide(I): ##STR00002## Development Code--AN019 The invention also relates to processes for the

The invention refers to a pharmaceutical composition having enhanced antitumor activity and/or reduced side effects. A significant portion of antitumor agents (cytostatics) destroy tumor cells acting partially via inhibiting the synthesis of DNA and RNA, and partially via damaging the completed DNA.

The present invention relates to the use of diltiazem as an agent for enhancing the therapeutic effect of the antitumor agents vincristine and doxorubicine in a composition which comprises as the active ingredient diltiazem or a pharmaceutically acceptable acid addition salt thereof for the

FIELD OF INVENTION The present invention relates to 4-piperidone derivatives possessing antineoplastic activities and their use in the treatment of cancer. BACKGROUND OF THE INVENTION A number of .alpha.,.beta.-unsaturated ketones display cytotoxic and anticancer properties (Dimmock et al, Curr.

BACKGROUND OF THE INVENTION A number of acridinylaminomethanesulfonanilide derivatives have recently been studied for antitumour activity. AMSA or 4'-(9-acridinylamino) methanesulfonanilide was found to show high antitumour activity in L1210 leukaemia screening systems (see G. J. Atwell, B. F. Cain

FIELD OF THE INVENTION The present invention relates to an anticancer agent containing arctigenin. More particularly, the present invention relates to an anticancer agent containing arctigenin with the dosage per day thereof being 100 mg or more. BACKGROUND ART A pancreas cancer is one of the

TECHNICAL FIELD OF THE INVENTION The present invention relates to liposomal encapsulated taxane and other antineoplastic drugs. BACKGROUND OF THE INVENTION The use of taxanes, such as paclitaxel, as anti-tumor agents for patients suffering from diseases, such as ovarian and breast cancer, is known.

This invention relates to 2-substituted estra-1,3,5(10)-trien-3-yl sulfamates and their use for the production of pharmaceutical agents that have an antitumor-active activity. Microtubuli are organelles that occur in most eukaryotic cells and take over a number of functions there such as mitosis,

The present invention relates to 2-[2-[(2-hydroxyethyl)amino]ethyl]-5-[[2-methylamino)ethyl]amino]indazolo[ 4,3-gh]isoquinolin-6(2H)-one and the pharmaceutically acceptable acid addition salts thereof. This compound has shown a high antitumor activity. PRIOR ART Some

CROSS REFERENCE TO RELATED APPLICATIONS This application is a National Stage of International Application No. PCT/CN2015/087945 filed Aug. 24, 2015, claiming priority based on Chinese Patent Application No. 201410425510.3 filed Aug. 26, 2014, the contents of all of which are incorporated herein by

The invention refers to a pharmaceutical composition having enhanced antitumor activity and/or reduced side effects. A significant portion of antitumor agents (cytostatics) destroy tumor cells acting partially via inhibiting the synthesis of DNA and RNA, and partially via damaging the completed DNA.

Indole-3-glyoxlamides have a variety of uses as pharmacodynamically active compounds and as synthetic building blocks in pharmaceutical chemistry. In the patent application Neth. Appl. 6502481, compounds are described which have an anti-inflammatory and antipyretic activity profile and analgesic

BACKGROUND OF THE INVENTION 1. Field of the Invention Indole-3-glyoxylamides have a variety of uses as pharmacodynamically active compounds and as synthetic building blocks in pharmaceutical chemistry. 2. Background Information In the patent application Neth. Appl. 6502481, compounds are described

The present invention relates to the use of triazine and pyrimidine compounds for obtaining medicaments that reverse resistance to anti-cancer and anti-malarial agents. A number of triazine and pyrimidine compounds having valuable pharmacological properties are known in the literature. Some of these